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Virtually all cases of invasive cervical cancer are associated with infection by high-risk 
strains of human papilloma virus. Effective primary and secondary prevention programs, 
as well as effective treatment for early-stage invasive cancer have dramatically reduced 
the burden of cervical cancer in high-income countries; 85% of the mortality from 
cervical cancer now occurs in low- and middle-income countries. This article provides 
an overview of challenges to cervical cancer care in sub-Saharan Africa (SSA) and 
identifies areas for programmatic development to meet the global development goal to 
reduce cancer-related mortality. Advanced stage at presentation and gaps in prevention, 
screening, diagnostic, and treatment capacities contribute to reduced cervical cancer 
survival. Cost-effective cervical cancer screening strategies implemented in low resource 
settings can reduce cervical cancer mortality. Patient- and system-based barriers need 
to be addressed as part of any cervical cancer control program. Limited human capacity 
and infrastructure in SSA are major barriers to comprehensive cervical cancer care. 
Management of early-stage, locally advanced or metastatic cervical cancer involves mul-
tispecialty care, including gynecology oncology, medical oncology, radiology, pathology, 
radiation oncology, and palliative care. Investment in cervical cancer care programs in 
low- and middle-income countries will need to include effective recruitment programs to 
engage women in the community to access cancer screening and diagnosis services. 
Though cervical cancer is a preventable and treatable cancer, the challenges to cervical 
control in SSA are great and will require a broadly integrated and sustained effort by 
multiple stakeholders before meaningful progress can be achieved.
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CeRviCAL CANCeR AND THe wAY TO MeeT  
GLOBAL DeveLOPMeNT GOAL
Cervical cancer is a significant cause of cancer-related mortality for women living in sub-Saharan 
Africa (SSA). In 2013, 39 out of 48 countries, classified as part of SSA region, identified cervical 
cancer as the most common cause of cancer-related death for women, followed by breast cancer (1). 
Collectively, the 236,000 women who died from cervical cancer in 2013, 90% of them in developing 
nations, represent a failure of the health system to implement a functional cervical cancer control 
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strategy (2). The human and societal cost of cervical cancer in 
SSA is difficult to estimate. The average age at diagnosis is 48; in 
SSA, most women in this age are subsistence farmers, supporting 
four to seven or more children. Facilities to treat cervical cancer 
are scarce in SSA. When surgery and other medical care are avail-
able, families face a significant risk of debt and worsened poverty 
from both the costs of treatment and loss of work (3).
Many challenges stand in the path to develop a health system 
to address the rising incidence of cancer in SSA, including 
changing demographics, deficiencies of infrastructure and 
human capacity, and financial constraints. Multiple steps exist 
to optimize cervical cancer control: primary prevention with 
human papilloma virus (HPV) vaccine, secondary prevention 
with national screening program with HPV DNA test, cytology 
or visual inspection with acetic acid (VIA), and treatment for 
invasive cancer. More than 40% of the SSA population is younger 
than 15 years, and the aging of this population will contribute 
to a rapidly increasing burden from cervical cancer on these 
communities (4).
In the context of HPV vaccine where the target age for vaccina-
tion of girls and boys is 11 or 12, this young demographic profile 
in SSA nations can be harnessed to yield greater reward for an 
investment in primary cervical cancer prevention. The cost of cur-
rent HPV vaccine is prohibitory for most SSA nations; the GAVI 
alliance, however, can make this investment more manageable for 
qualifying nations (5, 6). Models of HPV vaccination in SSA have 
shown that population-wide programs are highly cost-effective 
under various circumstances for both the quadrivalent and non-
avalent vaccines (7). The current HPV vaccines are heat-labile 
and, therefore, require an effective “cold-chain” of refrigeration 
between production and patients. In SSA, where transportation 
is poor and supply chains can be unreliable, and where 80% of 
the population still lives in rural settings (World Bank), extensive 
and coordinated planning is needed to effectively vaccinate a 
high proportion of the population. The stunning success of the 
Rwandan vaccination effort is a demonstration of the value of 
meticulous planning and execution in large-scale implementa-
tions (8).
Invasive cervical cancer typically develops 10–30  years 
after primary HPV infection. Even the most effective vaccina-
tion program, therefore, would leave millions of women who 
are potentially already infected with HPV, at risk for cervical 
cancer. Screening and cervical cancer treatment are, therefore, 
critical components of cervical cancer control over the coming 
generation.
Screening for cervical cancer precursors can be achieved 
through the use of cytology, HPV DNA testing, or VIA. Cytology-
based screening has been the basis of secondary screening 
in high-income countries for many decades. Cytology-based 
screening requires an extensive infrastructure, including reliable 
laboratories with reagents, specialized staff to read the specimens, 
information systems to notify patients, and caregivers of results 
and expectations for follow-up, and quality control processes for 
all of these components. The diagnostic performance of cytology-
based testing, furthermore, is highly variable, with limited sensi-
tivity and specificity in even optimal circumstances. The WHO 
recommends that only countries with established, high-quality 
programs with broad coverage of their target population utilize 
cytology-based screening (9).
Visual inspection with acetic acid has been advocated as a 
low-cost means of population-based screening. The advantages 
of VIA include limited infrastructure needs, limited initial cost, 
and an immediate diagnostic result, which in turn allows for 
“see and treat” programs in which women can be diagnosed and 
treated for pre-invasive cervical lesions in a single visit, limiting 
the burden on both patients and the health system by decreasing 
the need for patient tracking and follow-up (9). VIA has disad-
vantages as well. It is a subjective test: sensitivity and specificity 
vary with practitioner performance, making quality control a 
challenge as programs scale-up from closely monitored research 
settings to population-based screening. Because of the limited 
sensitivity of VIA, multiple rounds are needed in a woman’s life-
time. A study led by Shastri and colleagues found that multiple 
rounds of VIA decreased death from cervical cancer, but did 
not decrease the incidence of cervical cancer, suggesting that 
any positive effect may have been more from a stage shift rather 
than prevention of invasive cancer per  se (10). In SSA, where 
resources for the treatment of invasive cancer are limited, this 
might further decrease the benefit of VIA while increasing the 
burden on the health-care system and target population. The 
costs of the health-care work force and facility resources need 
to be accounted for during any new national cervical cancer 
screening program. As programs scale-up to population-based 
screening, robust information systems are needed to manage 
coverage of those at risk, schedule repeat screening, and avoid 
redundant testing.
Human papilloma virus testing offers advantages over cytology 
and VIA. It is an objective test, and, therefore, decreases the demands 
for human capacity and simplifies quality control. The high sensi-
tivity and negative predictive value of HPV testing makes a single 
lifetime test a reasonable option for women who test negative.
As articulated by Farmer, global health programs, including 
in this case effective cervical cancer control, require “space, staff, 
stuff, and systems” (11). In other words, medical interventions 
will be sustainably effective and able to respond to crises when 
a robust health infrastructure is in place. Unfortunately, health 
infrastructure is a huge challenge in SSA as has been recently 
elaborated through the work of the Lancet Commission on 
Global Surgery and others (3, 12). As shown in Table  1, our 
experience and that of others suggest that the following are 
salient challenges to cervical cancer control in SSA: clinical 
diagnostic capacity, capacity for processing and diagnosis of 
pathology specimens, a lack of oncology specialists at all levels, 
a deficiency of operating theaters and other surgical services, 
a lack of radiotherapy equipment and staff (13), and locally 
contextual factors, including poverty and the financial barriers 
to treatment, religious and cultural beliefs and stigmas around 
illness and cancer, and other medical morbidities, particularly 
coexisting infections, such as HIV, poor nutrition, and obstet-
rical fistulae. Developing health systems are challenged in 
resource allocation across many non-communicable diseases. 
Ultimately, success of any cancer treatment program must take 
into account the burden of treatment for the patient and her 
family.
TABLe 1 | essentials to a cervical cancer management program.
elements to consider
What is the clinical diagnostic capacity? •	 Cervical cancer awareness among health professionals
•	 Trained women’s health-care providers (pelvic exam, cervical biopsy)
What is the pathologic diagnostic capacity? •	 The who, how, and where of performing cervical disease pathology analysis
Human resources capacity in cervical 
cancer care
•	 Trained advanced gynecology surgeons or gynecologic oncologist, radiation oncologist, professional nurses, social 
workers
Access to cancer surgical services •	 Operative room facilities, post-surgical recovery units, access to intensive care units
•	 Surgical support team (nurses, doctors)
•	 Essential surgical supplies and medicines
Radiation oncology facilities •	 In-country or out-of-country radiation facility
•	 Limitations due to cost and distance to facility
Contextual modifiers •	 Financial barriers for patients and health system
•	 Religious and cultural beliefs toward cancer care
•	 Lack of care givers
•	 Significant medical comorbidities (Urinary obstruction or fistula, HIV status, poor nutritional status)
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To date, the majority of cervical cancer control programs 
in SSA are “vertical” efforts focused on primary or secondary 
prevention. We use the term “vertical” to describe interventions 
that are strictly focused on a single disease or condition. Given 
the paucity of medical infrastructure in SSA, this is most likely 
the most appropriate choice from the perspective of the single 
disease. Over time, however, very significant investments have 
been made in single disease-focused programs without lasting 
improvement of the overall health infrastructure (14). The U.S. 
invests $323 million each year for control of HIV in Uganda alone 
(15), but the sustained effect on medical infrastructure is unclear. 
Brown and colleagues found that, in Botswana, engagement in 
HIV treatment services was not associated with a decrease in the 
typically long interval between initial symptoms and diagnosis 
of cancer (16). We propose that more effort should be made to 
strengthen control of diseases within the rubric of overall health 
system strengthening.
TReATMeNT FOR iNvASive CeRviCAL 
CANCeR iN SUB-SAHARAN AFRiCA
Primary and secondary prevention of cervical cancer are far more 
cost-effective than the treatment for invasive cancer and should 
rightfully be placed as the highest priority of any new cervical 
cancer control effort. Increasing cancer screening, especially in 
a context where screening has not been ongoing, will identify 
women with invasive cancers, incurring an ethical and functional 
need for management. If a screening program can offer no treat-
ment or comfort for these women, it will both constitute a breach 
of implied trust and potentially turn the surrounding community 
against the program and future cancer control initiatives.
The treatment for invasive cervical cancer is determined by 
the stage of cancer at patient presentation and can range from 
minor surgery to radical surgery, chemotherapy, and radio-
therapy. The development of cervical cancer treatment services 
requires advanced-level services within a broader integrated 
health system that includes robust information systems, a func-
tioning consultation and referral network, diagnostic services 
including pathology and radiology, staffed and functioning 
operating rooms, perioperative care, radiotherapy services, and 
chemotherapy. In short, comprehensive management of invasive 
cervical cancer requires a breadth of services from primary to 
tertiary care. This raises a conundrum for nations planning a 
comprehensive cervical cancer control program: the greatest 
successes will only be seen when a broad and effective health 
system has been implemented. The exception to this is primary 
prevention: in our opinion, any effort to control cervical cancer 
should begin with the steps to implement a comprehensive HPV 
vaccination program, as this is known to be highly effective. A 
well-orchestrated campaign in a limited resource health system 
may succeed before the elements of an integrated and high-quality 
health system are in place. We do not, however, advocate HPV 
vaccination as a stand-alone program for cervical cancer control: 
given the 10–30 interval from HPV infection to the development 
of invasive cancer, millions of women already infected will be at 
risk for the next few decades.
The development of screening and treatment for cervical 
cancer faces significant challenges in SSA, including in informa-
tion systems, human capacity, and health system infrastructure. 
Poverty also has a significant effect on cervical cancer control; 
accommodations should be made to render screening, preven-
tion, and treatment feasible and affordable.
Health information systems in SSA are faced with high 
rates of illiteracy, limited health-specific knowledge, limited 
Internet capacity, and limited equipment for medical record-
keeping. Most of the patients in SSA are the keepers of their 
medical record often traveling with medical cards across clinic. 
Increasingly, individual hospitals are successfully implementing 
electronic medical records and thereby facilitate improved coor-
dination of care- and outcome-based research. The use of the 
OpenMRS platform at AMPATH in Eldoret, Kenya is an excel-
lent example (17). Improved patient identification and health 
information systems will be needed for cervical cancer control. 
Recordkeeping is critical to facilitate recruitment and follow-up 
in screening and prevention and is central to the consultation 
and referral.
Mobile technology has been found to be effective in improving 
both recruitment and adherence in the treatment for HIV in SSA 
TABLe 2 | Delays in diagnosis and treatment for cancer in low resource 
settings.
Patient delays •	 Limited awareness of cancer
•	 Limited expectation of cure or palliation
•	 Fear of financial ruin
•	 Competing demands for time, money
•	 Distance to treatment facility
Provider delays •	 Limited training in cancer diagnosis
•	 Competing/more acute clinical demands
•	 Limited expectation of cure or palliation
Referral Delays •	 Unclear referral networks
•	 Absent or unavailable specialists 
•	 Limited information systems/medical record technology
Diagnostic delays •	 Lack of sufficient pathology facilities and personnel
•	 Backlog of specimens 
•	 Limited information systems for results reporting and 
follow-up with patients and providers
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(18), and active efforts are underway to refine the role of these 
technologies in recruitment and follow-up of cervical cancer 
screening patients. Many countries in SSA have both high rates 
of cell phone ownership and extensive areas of cellular cover-
age (19). While mobile technology can be developed to support 
vertical cervical cancer-specific prevention programs, thought 
should be given to developing information systems in the context 
of and in concern with developing electronic medical records in 
the overall health system.
Treatment for invasive cervical cancer varies with stage at 
diagnosis. For patients with cancer limited to the cervix, surgery 
is often the treatment of choice, while for women with more 
advanced cancer, chemotherapy and radiotherapy are usually 
needed. Cervical cancer survival is compromised when patients 
present at advanced stage in high-income countries, where 
complex multimodality treatments are available. In SSA, where 
treatment for advanced disease is typically not readily avail-
able, this trend is accentuated (12, 20). Delays in presentation 
and diagnosis can be defined as discrete components: patient 
delay, health-care providers’ delay, referral delay, and diagnostic 
waiting time (Table 2) (21). Patient delay in SSA is understand-
able: due to better treatment for infectious diseases, decreased 
food insecurity, and an aging population, cancer is a relatively 
new problem, and many people, especially in remote settings, 
may have little knowledge of the disease. Even if patients have 
awareness of cancer, they may risk stigma or financial ruin with 
diagnosis and treatment. A woman diagnosed with cervical 
cancer may face abandonment or rejection from her spouse or 
community (22). Cervical cancer, furthermore, may present with 
pain bleeding or fistula formation: all issues that may be socially 
difficult to address in certain contexts. In areas with limited 
medical care, cancer may often be seen as a “death-sentence,” 
making diagnosis even less worth the social risk. Even in areas 
where some level of medical insurance is available, it is common 
for families to face bankruptcy from medical care (23). Surgery 
and chemotherapy, when available, often require out-of-pocket 
expenditures, and time lost from work can be devastating for a 
patient and her family living on subsistence farming or otherwise 
in or close to poverty (24). Addressing patient delays, therefore, 
requires advocacy and public awareness, but more importantly 
requires structuring the health system and social support such 
that people are not risking insolvency if they seek care for symp-
toms or signs of cancer.
Qualified medical staff are scarce in SSA (25), and those 
who are available have been trained to manage infectious and 
other acute illnesses using limited resources; these practitioners 
often have received limited training in cancer diagnosis and 
management. There is the potential for patients to present to a 
medical facility with cancer and to go undiagnosed, leading to a 
health-care provider delay. In addition, high clinical demands, 
limited training about cancer and cancer treatment resources, 
limited information technology, and either an absence or inac-
cessibility of specialists may lead to referral delays. As discussed 
earlier, improvements in information technology may help; 
certainly, there are many examples of the use of connectivity to 
bring specialty expertise to remote locations (26). In SSA, there 
are few trained oncology providers; although relationships with 
outside specialists may help guide care in tertiary centers, it is 
less clear how to provide guidance for providers at the primary 
level.
In cases where cancer is suspected, there may be significant 
diagnostic waiting time. Diagnostic pathology facilities and staff 
are scarce, and diagnostic testing may be costly for the patient. 
Often backlogs of specimens develop (27), and this may be 
exacerbated by limited information systems, making follow-up 
for results cumbersome.
Late-stage of cervical cancer at presentation in SSA is, 
therefore, a highly complex multifactorial issue that both arises 
from and limits the growth of effective cancer control programs. 
Addressing the various gaps in care will require a comprehensive 
and integrated approach to each of these factors, from the effects 
of poverty on family and social structures to the training and 
availability of oncology specialists.
HUMAN ReSOURCe CAPACiTY FOR 
CeRviCAL CANCeR SeRviCeS
Cervical cancer treatment is multimodal. Early stages of cervical 
cancer can be treated with curative oncologic surgery, whereas 
advanced or recurrent cervical cancer is best managed with 
radiation therapy and chemotherapy (28). Current capacity 
to provide comprehensive women’s cancer care in low- and 
middle-income countries is constrained by shortage in surgeons 
trained and experienced in oncologic surgery. The challenge to 
health-care human resources in LMICs encompasses all levels 
of the health-care work force, and innovative models to increase 
the capacity and capability of the health-care work force based on 
each region-specific conditions are fundamental to any national 
cancer control program. The current state of the surgical work-
force in LMICs is in crisis, directly impacting oncologic surgical 
services.
The WHO estimates that 57 countries globally face a critical 
shortage of health professionals, and the number of surgeons 
and anesthesiologists are particularly scarce (29). Thirty-six 
of these countries are in SSA, where surgeon density maybe as 
low as 0.5 per 100,000 people (30, 31). Although the number 
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of health-care work force is only one of the factors impacting 
surgically treatable conditions, certainly, addressing this dire 
shortage in surgical work force will advance the neglected area 
of oncologic global health. An estimated 234.2 million major 
surgical procedures are performed worldwide each year, 3.5% of 
the procedures are performed among the poorest one-third of 
the world’s population, pointing to a large unmet surgical need 
(32). Limited data exist on the number of oncology specialist 
in SSA, but reflecting on the state of the health work force in 
LMIC’s, it can be assumed that health professionals trained 
in cancer care are soulfully lacking (33). In a report of radia-
tion services in Nigeria, with a population of 160 million and 
estimated of 100,000 new cancer cases annually, there were 
18 radiation oncologist, 8 medical physicists, and 18 radia-
tion therapist to meet the nations radiation therapy (34,  35). 
Countries such as Rwanda are developing innovative models 
to meet the challenges, such as task shifting and partnerships, 
between high resource and low resource cancer centers (36). 
Beyond the LMIC’s countries, challenges to meet the demands 
of an aging population on oncology services are anticipated in 
high-resource countries.
Challenges identified in meeting the demand for essential 
surgical services in LMIC’s include “brain drain,” the phe-
nomena of losing trained staff from LMICs to high-income 
countries (37). World Health Organization (WHO) Global 
Initiative for Emergency and Essential Surgical Care (GIEESC) 
was launched in 2005 with the goal to scale access and delivery 
of surgical care in LMICs. The WHO Global Code of Practice 
on the International Recruitment of Health Personnel rec-
ognizes that a strong health system is critical to economic 
development of a nation and proposed a framework to address 
the shortage and migration of health-care work force in LMICs 
(38). A key component of supporting this WHO Global Code 
is for high-income countries to meet their own demand for 
health-care force by increasing training in their own country. 
In addition, a positive outcome of this code is the increased 
support of high-income countries by providing technical and 
monetary assistance for addressing health-care force shortage 
in LMICs.
ACCeSS AND AvAiLABiLiTY OF 
PALLiATive SeRviCeS AND MeDiCiNeS 
iN LOw ReSOURCe SeTTiNGS
Globally, lack of access to palliative care services and strong pain 
medications limit the quality of care patients with advanced or 
end stage cervical cancer can receive. A significant number of 
women in low resource settings present with advanced cervical 
cancer. At the time of presentation, cervical cancer symptoms 
of bleeding, pain, or urinary dysfunction can be debilitating to 
the patient (39). Approximately 40% of women diagnosed with 
cervical cancer in a tertiary center in India were staged III and 
IV (40). In addition, delay in diagnosis and time to initiation of 
treatment can be significant, resulting in progression of the dis-
ease and associated symptoms. Among cervical cancer patients 
in Ethiopia, 63% of patients were ultimately stage IIB/IV at the 
time of evaluation for radiation therapy (41). Patients allocated 
to palliative care group experienced the most significant delay 
in care (41). A similar pattern of disease presentation has been 
documented among underserved women in high resource 
setting (39). The loss of quality of life attributed to cervical 
cancer diagnosis is not limited to end stage disease. Patients with 
early-stage cervical cancer undergoing curative intent treatment 
experience significant anxiety, depression, sexual dysfunction, 
and treatment side effects, best managed by a multidisciplinary 
team approach (42).
Palliative care services can be implemented in every resource 
setting. Team approach to the palliative care is therapeutic to 
the patient, family, and health-care provider. A nurse, doctor, 
and social worker are integral to the team. As resources allow, 
skills provided by physical therapist, pain and palliative care 
physicians, and oncologist enhance the quality of palliative 
care services (43). Palliative cancer care provides improvement 
in quality of life with reduced health-care utilization when 
implemented early in the course of cancer management (44, 
45). Cervical cancer patients may experience loss of appetite, 
fatigue, vaginal bleeding/hemorrhage, and pelvic pain that 
improve with initiation of cancer treatment. As cervical 
cancer progresses, pain, renal dysfunction, and fistulas can be 
hallmark of the disease. Pain management utilizing the WHO 
pain ladder remains the standard with incremental increase 
from non-narcotic to narcotic drugs (46). Establishing access 
to morphine is critical to alleviating patients suffering. Few 
global health priorities supersede the critical shortage in 
pain management in low resource setting (47). A margin 7% 
of medical use of opioids occurs in middle- and low-income 
countries, thus compounding barriers to palliative cervical 
cancer care (48).
CONCLUSiON
In 2016, the means to prevent and treat cervical cancer are well 
known and widely available; a death from cervical cancer should 
be understood as a preventable and unnecessary death. The ben-
efit from vaccination programs will not be realized for decades, 
leaving millions of women at risk. In areas with limited medical 
resources, programs of primary and secondary prevention can 
significantly decrease the burden of cervical cancer. Complete 
and comprehensive cervical cancer control, however, requires a 
broadly coordinated effort from multiple specialists and facilities. 
These specialists can only be trained, and such care can only be 
safely given, in the setting of a strong overall health system. We 
propose that outreach efforts in cervical cancer control should 
broaden their targets beyond process-based and disease-based 
metrics and work to more broadly strengthen the overall health 
system.
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